Madhup Rastogi1, Rohini Khurana2, Swaroop Revannasiddaiah3, Isha Jaiswal2, Sambit S Nanda4, Pooja Gupta5, Kundan S Chufal6, M L Bhatt7. 1. Department of Radiation Oncology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Vibhuti Khand, Gomti Nagar, Lucknow, 226010, India. drmadhup1@rediffmail.com. 2. Department of Radiation Oncology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Vibhuti Khand, Gomti Nagar, Lucknow, 226010, India. 3. Department of Radiotherapy, Government Medical College, Haldwani, India. 4. Department of Radiotherapy, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India. 5. Department of Radiotherapy, Medanta The Medicity, New Delhi, India. 6. Department of Radiotherapy, Batra Hospital and Medical Research Centre, New Delhi, India. 7. Department of Radiotherapy, King George's Medical College, Lucknow, India.
Abstract
PURPOSE:Benzydamine is recommended for prophylaxis of oral mucositis (OM) in head and neck cancer (HNC) patients for radiation doses (<50 Gy). This study evaluates role of benzydamine for higher radiation doses (>50 Gy) with or without chemotherapy. METHODS:One hundred twenty patients of HNC with planned radiation doses of ≥60 Gy were randomized to group A (control radiotherapy alone), group B (study radiotherapy alone), group C (control chemoradiotherapy), or to group D (study chemoradiotherapy). Groups A and C were advised saline mouth rinses, and in groups B and D, additional benzydamine rinses (0.15%) were advised. Mucositis grading was done with both WHO (WHO-M) and CTCAE (CTC-M) version 4.0 (common terminology criteria for adverse events) weekly. RESULTS: Patient characteristics are presented in the table. Patients in group B had lesser grade 3 WHO-M and CTC-M as compared to group A, 62.1 vs. 36.4% (p = 0.038) and 51.7 vs. 27.3% (p = 0.043), respectively. The rates of Ryle's tube feeding (RTF), intravenous fluid supplementation (IVF), and hospitalization were also lesser in group B as compared to A, 34.5 vs. 21.2% (p = 0.18), 27.6 vs. 9.1% (p = 0.06), and 6.9 vs. 0% (p = 0.21), respectively. WHO-M and CTC-M in groups C and D were not statistically different, 64.3 vs. 43.3% (p = 0.091) and 53.6% vs. 43.3% (p = 0.30), respectively. The rates of RTF, IVF, and hospitalization were all lesser but p > 0.05. CONCLUSION:Benzydamine significantly reduces OM even at doses >50 Gy in HNC patients. Its role in patients receiving concurrent chemotherapy further needs to be evaluated.
RCT Entities:
PURPOSE:Benzydamine is recommended for prophylaxis of oral mucositis (OM) in head and neck cancer (HNC) patients for radiation doses (<50 Gy). This study evaluates role of benzydamine for higher radiation doses (>50 Gy) with or without chemotherapy. METHODS: One hundred twenty patients of HNC with planned radiation doses of ≥60 Gy were randomized to group A (control radiotherapy alone), group B (study radiotherapy alone), group C (control chemoradiotherapy), or to group D (study chemoradiotherapy). Groups A and C were advised saline mouth rinses, and in groups B and D, additional benzydamine rinses (0.15%) were advised. Mucositis grading was done with both WHO (WHO-M) and CTCAE (CTC-M) version 4.0 (common terminology criteria for adverse events) weekly. RESULTS:Patient characteristics are presented in the table. Patients in group B had lesser grade 3 WHO-M and CTC-M as compared to group A, 62.1 vs. 36.4% (p = 0.038) and 51.7 vs. 27.3% (p = 0.043), respectively. The rates of Ryle's tube feeding (RTF), intravenous fluid supplementation (IVF), and hospitalization were also lesser in group B as compared to A, 34.5 vs. 21.2% (p = 0.18), 27.6 vs. 9.1% (p = 0.06), and 6.9 vs. 0% (p = 0.21), respectively. WHO-M and CTC-M in groups C and D were not statistically different, 64.3 vs. 43.3% (p = 0.091) and 53.6% vs. 43.3% (p = 0.30), respectively. The rates of RTF, IVF, and hospitalization were all lesser but p > 0.05. CONCLUSION:Benzydamine significantly reduces OM even at doses >50 Gy in HNC patients. Its role in patients receiving concurrent chemotherapy further needs to be evaluated.
Authors: Deborah B McGuire; Maria Elvira P Correa; Judith Johnson; Patricia Wienandts Journal: Support Care Cancer Date: 2006-04-25 Impact factor: 3.603
Authors: Dorothy M Keefe; Mark M Schubert; Linda S Elting; Stephen T Sonis; Joel B Epstein; Judith E Raber-Durlacher; Cesar A Migliorati; Deborah B McGuire; Ronald D Hutchins; Douglas E Peterson Journal: Cancer Date: 2007-03-01 Impact factor: 6.860
Authors: Edward B Rubenstein; Douglas E Peterson; Mark Schubert; Dorothy Keefe; Deborah McGuire; Joel Epstein; Linda S Elting; Philip C Fox; Catherine Cooksley; Stephen T Sonis Journal: Cancer Date: 2004-05-01 Impact factor: 6.860
Authors: Andy Trotti; Lisa A Bellm; Joel B Epstein; Diana Frame; Henry J Fuchs; Clement K Gwede; Eugene Komaroff; Luba Nalysnyk; Marya D Zilberberg Journal: Radiother Oncol Date: 2003-03 Impact factor: 6.280
Authors: Rajesh V Lalla; Joanne Bowen; Andrei Barasch; Linda Elting; Joel Epstein; Dorothy M Keefe; Deborah B McGuire; Cesar Migliorati; Ourania Nicolatou-Galitis; Douglas E Peterson; Judith E Raber-Durlacher; Stephen T Sonis; Sharon Elad Journal: Cancer Date: 2014-02-25 Impact factor: 6.860
Authors: Desiderio Passali; Maria Felice Arezzo; Alessandra De Rose; Gianmarco De Simone; Gianluigi Forte; Michalina Jablko-Musial; Ralph Mösges Journal: BMC Prim Care Date: 2022-06-17
Authors: Clifton P Thornton; Mengchi Li; Chakra Budhathoki; Chao Hsing Yeh; Kathy Ruble Journal: Support Care Cancer Date: 2022-04-29 Impact factor: 3.359